Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

New evidence establishes elevated protease activity as highly predictive of skin graft failure

Systagenix : 17 May, 2013  (Company News)
New evidence presented at the European Wound Management Association (EWMA)'s conference in Copenhagen, Denmark revealed that elevated protease activity (EPA) was detected in almost half the wounds (43 percent) that resulted in skin graft failure.


In the thirty patient study carried out and presented by Prof Franck Duteille MD, Head of Department of Plastic Reconstructive and Aesthetic Surgery, University Hospital, Nantes, France, three out of four (75 percent) split thickness skin grafts failed in wounds that tested positive for EPA immediately prior to performing the graft procedure1 . This confirms EPA as a highly predictive marker which could help surgeons target skin graft procedures more effectively and thus increase their success rates.



"Systagenix's WOUNDCHEK Protease Status is the only commercially available point of care test able to detect EPA," commented Paolo Di Vincenzo, Systagenix Vice President Global Marketing. “Studies continue to show the utility of testing for EPA with WOUNDCHEK Protease Status in helping guide treatment and increase success rates. In Prof. Duteille's study, 96 percent of grafts that succeeded had low protease activity. For the grafts that failed, almost half of them were associated with EPA. With graft procedures costing up to €6,0002, and resulting in a significant amount of patient discomfort, any failure rate is too high. By testing for EPA with WOUNDCHEK Protease Status, surgeons may be able to increase their success rates by avoiding almost half of their failed graft procedures and saving a substantial amount of resource, and funds, as well as avoiding a disappointing setback for the patients affected.”



Clinicians have long suspected the detrimental effect of protease activity on skin graft ability to take, as described in a recent consensus publication on this topic: 'A point of care protease activity test could be used prior to use of skin grafts in order to improve the success rate of surgery as EPA has been identified as a possible contributing factor to graft failure'.


Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo